XETRA - Delayed Quote EUR

AbbVie Inc. (4AB.DE)

Compare
172.44
+0.76
+(0.44%)
At close: January 10 at 5:35:33 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
55,533,000.00
54,318,000.00
58,054,000.00
56,197,000.00
45,804,000.00
Cost of Revenue
18,212,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
Gross Profit
37,321,000.00
33,903,000.00
40,640,000.00
38,751,000.00
30,417,000.00
Operating Expense
22,812,000.00
21,146,000.00
22,523,000.00
20,827,000.00
19,054,000.00
Operating Income
14,509,000.00
12,757,000.00
18,117,000.00
17,924,000.00
11,363,000.00
Net Non Operating Interest Income Expense
-1,928,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
Other Income Expense
-5,384,000.00
-4,823,000.00
-2,596,000.00
-2,551,000.00
-5,685,000.00
Pretax Income
7,197,000.00
6,250,000.00
13,477,000.00
12,989,000.00
3,398,000.00
Tax Provision
2,064,000.00
1,377,000.00
1,632,000.00
1,440,000.00
-1,224,000.00
Net Income Common Stockholders
5,081,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
Diluted NI Available to Com Stockholders
5,081,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
Basic EPS
2.87
2.73
6.65
6.48
2.73
Diluted EPS
2.87
2.72
6.63
6.45
2.72
Basic Average Shares
1,768,750.00
1,768,000.00
1,771,000.00
1,770,000.00
1,667,000.00
Diluted Average Shares
1,773,000.00
1,773,000.00
1,778,000.00
1,777,000.00
1,673,000.00
Total Operating Income as Reported
13,822,000.00
12,757,000.00
18,117,000.00
17,924,000.00
11,363,000.00
Total Expenses
41,024,000.00
41,561,000.00
39,937,000.00
38,273,000.00
34,441,000.00
Net Income from Continuing & Discontinued Operation
5,122,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
Normalized Income
5,648,351.81
4,976,880.00
11,966,092.00
11,587,339.00
4,667,830.00
Interest Income
742,000.00
540,000.00
186,000.00
39,000.00
174,000.00
Interest Expense
2,670,000.00
2,224,000.00
2,230,000.00
2,423,000.00
2,454,000.00
Net Interest Income
-1,928,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
EBIT
9,867,000.00
8,474,000.00
15,707,000.00
15,412,000.00
5,852,000.00
EBITDA
18,227,000.00
17,172,000.00
24,174,000.00
23,933,000.00
12,323,000.00
Reconciled Cost of Revenue
18,212,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
Reconciled Depreciation
8,360,000.00
8,698,000.00
8,467,000.00
8,521,000.00
6,471,000.00
Net Income from Continuing Operation Net Minority Interest
5,122,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
Total Unusual Items Excluding Goodwill
-738,000.00
-146,000.00
-148,000.00
-51,000.00
-71,000.00
Total Unusual Items
-738,000.00
-146,000.00
-148,000.00
-51,000.00
-71,000.00
Normalized EBITDA
18,965,000.00
17,318,000.00
24,322,000.00
23,984,000.00
12,394,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-211,648.19
-32,120.00
-17,908.00
-5,661.00
-19,170.00
12/31/2020 - 5/17/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6MK.DE Merck & Co., Inc.
97.70
+0.51%
 
RECm.XC
 
C43.DE Cosmo Pharmaceuticals N.V.
69.00
+0.73%
 
IDP.DE Biogen Inc.
144.80
-0.34%
 
ZEG.DE AstraZeneca PLC
131.25
+0.04%
 
1MRKX.MI MERCK & CO.
97.70
+0.51%
 
GIS.DE Gilead Sciences, Inc.
87.37
+1.35%
 
7XP.F Organon & Co.
15.54
+1.17%
 
1PFE.MI PFIZER
26.35
+1.72%
 
JNJ.DE Johnson & Johnson
139.68
+1.13%